中华结核和呼吸杂志最新文献_第8页

[An analysis of clinical and genetic feature in pulmonary artery sarcoma]. 肺动脉肉瘤的临床及遗传特征分析

中华结核和呼吸杂志 Pub Date : 2025-03-12 DOI: 10.3760/cma.j.cn112147-20240731-00450

Q Jiang, H Yan, C Huang, R Ma, C T Zhang, K Yang, J Wang, C L Liu

{"title":"[An analysis of clinical and genetic feature in pulmonary artery sarcoma].","authors":"Q Jiang, H Yan, C Huang, R Ma, C T Zhang, K Yang, J Wang, C L Liu","doi":"10.3760/cma.j.cn112147-20240731-00450","DOIUrl":"10.3760/cma.j.cn112147-20240731-00450","url":null,"abstract":"Objective: To retrospectively analyze the clinical, imaging, pathological and genetic features in patients with pulmonary artery sarcoma (PAS) in a single center, and to investigate the disease origin of PAS, as well as its relationship with other pulmonary vascular diseases. Methods: We retrospectively identified and analyzed clinical features of 13 cases with PAS those were admitted in the First Affiliated Hospital of Guangzhou Medical University between January 2015 and January 2021. Whole exome sequencing (WES) was performed to further analyze their genetic characteristics in 8 postoperative specimens. Results: The average age of PAS patients was 26-67 (43.2±11.6) years, and the median time from symptom to diagnosis was 8 months (IQR: 3, 11.5). The most common symptom of PAS was shortness of breath (84.6%), and the most common complication was pulmonary hypertension (69.2%).A total of 5 genes with specific mutations in PAS patients were identified by genomic analysis. Compared with genetic features of pulmonary embolism (PE), pulmonary arterial hypertension (PAH) and lung cancer (LC),we found genetic similarity between PAS and LC. Using KEEG database, we identified that most of the PAS-mutated genes belonged to cancer-enriched signaling pathways. Conclusions: PAS is a kind of malignant tumor located in the pulmonary vascular trunk, without a good prognosis and specific clinical manifstations. The occurrence of PAS may be associathed with mutations of MDM2, PIK3CA and TP53.","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"48 3","pages":"256-260"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20240517-00261

H Hao, W Wang, X M Ran, M Q Li, B C Liu, K J Wang

{"title":"[Immunorelated Stevens-Johnson syndrome/toxic epidermolysis caused by programmed death receptor 1 inhibitors: a case report].","authors":"H Hao, W Wang, X M Ran, M Q Li, B C Liu, K J Wang","doi":"10.3760/cma.j.cn112147-20240517-00261","DOIUrl":"10.3760/cma.j.cn112147-20240517-00261","url":null,"abstract":"Stevens-Johnson syndrome (SJS) and toxic epidermalnecrolysis (TEN) are acute, severe and fatal diseases involving the skin and mucous membranes, most commonly caused by pharmaceutical factors. These include various sensitizing antibiotics, non-steroidal anti-inflammatory drugs and so on. Immune-associated Stevens-Johnson syndrome/toxic epidermolysis caused by programmed death-1 (PD-1) inhibitors has not been reported. On April 11, 2024, a male patient with primary bronchial lung cancer (right lung squamous cell carcinoma T3N3M1b ⅣA phase driver gene KRAS G12S PD-L1 negative, PS 0 score) was admitted to the department of respiratory and critical care medicine of Bishan hospital affiliated to Chongqing medical university. On March 25, 2024, the patient underwent the 3rd cycle of anti-tumor therapy \"Tirellizumab 200 mg+albumin paclitaxel 400 mg+carboplatin 450 mg\", and on April 9, 2024, Stevens-Johnson syndrome and toxic epidermolysis occurred, and the epidermolysis area reached more than 95%. After permanent discontinuation of immunosuppressants, anti-infection, hormone, nutritional support, immunoglobulin and other comprehensive treatment, the patient was eventually cured and successfully discharged.","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"48 2","pages":"142-145"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Annual updates of respiratory infectious diseases in 2024]. [2024年呼吸道传染病年度更新]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20241218-00744

Y X Zhang, J M Qu

引用次数: 0

[Annual advances in clinical studies of chronic cough (2024)]. [慢性咳嗽临床研究年度进展（2024）]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20241122-00695

M T Lin, T T Xu, J Y Li, K F Lai

引用次数: 0

[A case of Legionella pneumophila pneumonia complicated by acute hemorrhagic leukoaraiosis and rhabdomyolysis]. [嗜肺军团菌肺炎合并急性出血性白质变伴横纹肌溶解1例]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20240616-00341

Q Y Yang, X L Meng, M Y Zhao, W L Kong

引用次数: 0

[Application of artificial intelligence in combination with CT radiomics in chronic obstructive pulmonary disease]. [人工智能结合CT放射组学在慢性阻塞性肺疾病中的应用]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20240830-00517

R Y Wang, W Sun, Z J Luo, J Wang

引用次数: 0

[Annual progress in diagnostic imaging of tuberculosis in 2024]. 【2024年结核病诊断影像学年度进展】。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20241031-00650

Y N Liang, D L Hou

引用次数: 0

[COVID-19 infection with tracheobronchomalacia: a case report]. [COVID-19感染气管支气管软化症1例报告]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20240730-00441

T Wang, X Chen, X P Shi, Y X He, Y P Li, W J Wu, L Liu, J Zhang, B Xue

引用次数: 0

[Annual review of bronchiectasis 2024]. 【支气管扩张年度回顾2024】。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20241121-00691

R Jiang, A J Yao, Y Q Wang, Abudukeyoumu Sayina, H Z Zheng, J F Xu

{"title":"[Annual review of bronchiectasis 2024].","authors":"R Jiang, A J Yao, Y Q Wang, Abudukeyoumu Sayina, H Z Zheng, J F Xu","doi":"10.3760/cma.j.cn112147-20241121-00691","DOIUrl":"10.3760/cma.j.cn112147-20241121-00691","url":null,"abstract":"Bronchiectasis (BE) is a chronic airway disease characterized by bronchial abnormalities and persistent dilation due to a variety of underlying causes. Over the past year, significant advances have been made in the study of bronchiectasis, particularly in the areas of epidemiology, microbiology, pathogenesis, comorbidities, and treatment. Recent studies have identified sputum color and nitrate/nitrite levels as prognostic biomarkers for exacerbations, while advances in exhaled breath biomarkers have improved screening and diagnosis, providing new insights into preventive and therapeutic targets for bronchiectasis. Significant progress has also been made in therapeutic research, including the development of dipeptidyl peptidase-1 inhibitors, inhaled colistimethate sodium and epithelial calcium channel blockers, all of which are helping to the advancement of precision medicine in bronchiectasis. The development of new-generation genome sequencing technology can further explore the pathogenesis of bronchiectasis from various aspects including genetics, epigenetics, transcriptomics and metabolomics. In conclusion, this review provides a concise overview of the major advances in bronchiectasis research from October 1, 2023 to September 30, 2024, with the aim of providing new perspectives for future research directions.","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"48 2","pages":"158-163"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical research progress in non-invasive positive pressure ventilation from 2023 to 2024]. [2023 - 2024年无创正压通气临床研究进展]。

中华结核和呼吸杂志 Pub Date : 2025-02-12 DOI: 10.3760/cma.j.cn112147-20241118-00683

Q Y Huang, S S Zha, L L Guan, Z F He, J Y Niu, R C Chen

{"title":"[Clinical research progress in non-invasive positive pressure ventilation from 2023 to 2024].","authors":"Q Y Huang, S S Zha, L L Guan, Z F He, J Y Niu, R C Chen","doi":"10.3760/cma.j.cn112147-20241118-00683","DOIUrl":"10.3760/cma.j.cn112147-20241118-00683","url":null,"abstract":"The present review conducted a comprehensive search and retrieval of clinical studies related to non-invasive positive pressure ventilation (NPPV) for acute respiratory failure (ARF) and chronic respiratory failure (CRF) retrieved from Medline between October 1, 2023 and September 30, 2024. In the treatment of ARF with NPPV, experiments using Digital Twins had shown that excessive tidal volumes associated self-inflicted lung injury might contribute to NPPV failure. The administration of sedation and analgesia during NPPV was found to correlate with increased mortality. In patients with acute exacerbations of chronic obstructive pulmonary disease, high-intensity NPPV significantly reduced intubation rates. However, high-flow nasal cannula oxygen therapy (HFNC) was less effective than NPPV when used as an initial treatment. In the management of CRF patients, a Franch study examined the pre-NPPV health trajectory of COPD patients receiving home NPPV based on French national health insurance reimbursement system database and suggested that the timing of initiation of home NPPV treatment significantly influenced prognosis. In addition, the research found that remote management utilizing Internet of Things technology enhanced patients' health-related quality of life and reduced the risk of hospital readmission. In terms of preventing re-intubation, different underlying conditions exhibited different responses to NPPV treatment. Specifically, prophylactic use of NPPV was found to reduce the risk of reintubation in obese surgical patients, but not in those with acute brain injury. In terms of technological advancements, Bag-CPAP, a device consisting of an oxygen storage bag and medium flow oxygen, has been validated as an alternative ventilation choice suitable for resource-limited settings.","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"48 2","pages":"154-158"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0